Repligen (NASDAQ:RGEN) Coverage Initiated by Analysts at Canaccord Genuity Group

Canaccord Genuity Group began coverage on shares of Repligen (NASDAQ:RGEN) in a research note issued on Tuesday. The brokerage set a “hold” rating and a $165.00 price target on the biotechnology company’s stock. Canaccord Genuity Group’s price target suggests a potential upside of 2.54% from the company’s current price.

Several other research firms also recently commented on RGEN. Wells Fargo & Company initiated coverage on shares of Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective for the company. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Wolfe Research began coverage on Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Finally, StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and an average target price of $187.44.

Repligen Trading Up 2.9 %

Shares of NASDAQ:RGEN opened at $160.92 on Tuesday. The business’s 50-day moving average is $142.66 and its 200 day moving average is $141.59. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13. The firm has a market capitalization of $9.02 billion, a P/E ratio of -434.92, a P/E/G ratio of 4.64 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.23 earnings per share. On average, research analysts predict that Repligen will post 1.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Repligen

Large investors have recently made changes to their positions in the company. Champlain Investment Partners LLC lifted its position in shares of Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after buying an additional 850,345 shares in the last quarter. Thrivent Financial for Lutherans increased its holdings in Repligen by 240.5% in the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock worth $75,866,000 after acquiring an additional 425,061 shares in the last quarter. Bank of New York Mellon Corp raised its position in Repligen by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after acquiring an additional 237,884 shares during the period. Conestoga Capital Advisors LLC lifted its holdings in Repligen by 26.7% during the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after purchasing an additional 199,322 shares in the last quarter. Finally, DF Dent & Co. Inc. grew its position in shares of Repligen by 31.0% in the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after purchasing an additional 139,615 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.